ALS 8123: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoic acid : A carboxylic acid that is 3-phenylpropanoic acid substituted at position 4 by a 2-hydroxy-3-(propan-2-ylamino)propoxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 133620 |
| CHEMBL ID | 767 |
| CHEBI ID | 143310 |
| SCHEMBL ID | 9354060 |
| MeSH ID | M0156424 |
| Synonym |
|---|
| benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)- |
| g0sm48n856 , |
| unii-g0sm48n856 |
| als 8123 |
| CHEMBL767 , |
| CHEBI:143310 , |
| 3-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}propionic acid |
| 81148-15-4 |
| 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoic acid |
| 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoic acid |
| als-8123 |
| bdbm50404792 |
| asl-8123 |
| esmolol acid |
| 3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propionic acid |
| esmolol hydrochloride impurity, esmolol free acida- [usp impurity] |
| (+/-)-esmolol acid |
| esmolol free acid [usp impurity] |
| (r)-esmolol acid |
| benzenepropanoic acid,4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- |
| SCHEMBL9354060 |
| 3-[4-[2-hydroxy-3-(isopropylamino)propoxyl] phenyl]propionic acid |
| FT-0667972 |
| Q27225688 |
| 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoic acid |
| DTXSID801001809 |
| esmolol acid (hydrochloride) |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic disposition of esmolol was not significantly altered by renal failure." | ( Pharmacokinetics of esmolol and ASL-8123 in renal failure. Flaherty, JF; Gambertoglio, JG; Hulse, JD; La Follette, G; Warnock, DG; Wong, B, 1989) | 0.28 |
| Class | Description |
|---|---|
| carboxylic acid | A carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid. |
| ethanolamines | |
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-1 adrenergic receptor | Cavia porcellus (domestic guinea pig) | Kd | 19.9526 | 0.0000 | 0.5358 | 8.3176 | AID39950 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID39950 | Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation | 1982 | Journal of medicinal chemistry, Dec, Volume: 25, Issue:12 | Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||